Shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) saw unusually-high trading volume on Friday . Approximately 295,341 shares traded hands during trading, a decline of 1% from the previous session’s volume of 299,231 shares.The stock last traded at $10.25 and had previously closed at $10.26.

Several equities research analysts recently commented on AIMT shares. Wedbush reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a report on Monday, May 16th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $38.00 price objective on shares of Aimmune Therapeutics in a research report on Tuesday, April 12th. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Friday, May 20th. Finally, Bank of America Corp. reiterated a “buy” rating on shares of Aimmune Therapeutics in a research report on Monday, May 16th. Five equities research analysts have rated the stock with a buy rating, Aimmune Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $33.40.

The stock’s market cap is $443.17 million. The firm has a 50 day moving average of $13.06 and a 200-day moving average of $14.66.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, May 16th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.03. Equities research analysts anticipate that Aimmune Therapeutics Inc. will post ($1.70) EPS for the current year.

In other Aimmune Therapeutics news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the firm’s stock in a transaction on Tuesday, May 31st. The stock was sold at an average price of $15.23, for a total transaction of $3,655,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

A number of institutional investors have modified their holdings of AIMT. Aisling Capital LLC increased its stake in Aimmune Therapeutics by 6.0% in the fourth quarter. Aisling Capital LLC now owns 2,990,000 shares of the company’s stock worth $55,166,000 after buying an additional 170,000 shares in the last quarter. TLP Group LLC purchased a new stake in Aimmune Therapeutics during the fourth quarter worth about $51,314,000. Alps Advisors Inc. purchased a new stake in Aimmune Therapeutics during the fourth quarter worth about $1,027,000. Finally, Eagle Asset Management Inc. purchased a new stake in Aimmune Therapeutics during the fourth quarter worth about $15,794,000.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.